The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 44.10
Bid: 44.10
Ask: 45.90
Change: 0.00 (0.00%)
Spread: 1.80 (4.082%)
Open: 44.10
High: 44.10
Low: 44.10
Prev. Close: 45.00
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of breakthrough purification system

16 Aug 2017 07:00

RNS Number : 0944O
Benchmark Holdings PLC
16 August 2017
 

 

Benchmark Holdings plc("Benchmark" or the "Company")

 

Benchmark pioneers environmentally benign purification system in the fight against sealice

 

Benchmark is pleased to announce it has developed a major industry breakthrough for the salmon industry, CleanTreat, a new fully contained purification system. Chemical based bath treatments that are released into water are one of the biggest objections to the salmon farming industry and CleanTreat works to solve this environmental challenge.

 

CleanTreat ensures the safe use of compounds in the marine environment by purifying the medicine from the treatment water to undetectable levels. The CleanTreat system is the first of its kind to be used in aquaculture, and will be administered in conjunction with Benchmark's next generation sealice treatment, which is currently in late stage development. The system can also be used with most licensed bath treatments.

 

CleanTreat is packaged in a standard ISO shipping container which allows for modular installation on board well-boats, treatment barges and land based systems. The system ensures that treatment water is purified and detached lice will be filtered and collected, achieving the highest level of environmental safety and also reducing the risk of future development of resistance.

 

The treatment plan will firstly be launched in the Norwegian market. The trials will see leading producers pilot the new system and product at commercial scale. The worldwide market for salmon is estimated to be worth 10.7bn USD per annum and the estimated cost of sealice for the global market is estimated to be 1bn USD.

 

Malcolm Pye, CEO of Benchmark commented:

"Sea lice are a major challenge for the sustainable growth of the salmon industry. Our main objective as a company is to produce innovative treatments which ensure the good health and welfare of farmed fish, that are highly efficacious and have no significant impact on the environment."

 

"The Benchmark Group has a growing toolkit of products and services, such as CleanTreat, alongside the launch in 2015 of sealice resistant salmon strains. Whilst there is no single 'silver bullet' to combat the sealice problem, Benchmark continues to invest in a range of new technologies to tackle the sea lice challenge, including biological control such as lumpfish production and vaccine development".

 

-ENDS-

 

Benchmark Holdings plc

Tel: 020 7920 3150

Malcolm Pye, CEO

Rachel Aninakwah, Communications

Numis

Tel: 020 7260 1000

Michael Meade / Freddie Barnfield (NOMAD)

James Black (Corporate Broking)

Tavistock

Tel: 020 7920 3150

Niall Walsh / Sophie Praill / Simon Hudson

 

 

Notes to Editors:

Benchmark challenges the status quo in aquaculture, agriculture and animal healthcare.

 

Since 2000, Benchmark has consistently worked to build a platform to serve its customers, helping farmers to take control of their biological environment through the combination of genetics, nutrition, health and knowledge services. Through its in-depth knowledge of animal biology Benchmark is able to tackle the key issues in the aquaculture, livestock and companion animal sectors.

 

The Company has proven distribution capabilities in high growth markets and operates internationally with R&D facilities, commercial farms, diagnostic laboratories, manufacturing sites, production facilities and commercial offices across 27 countries in five continents. As at 30 June 2017, Benchmark employed 951 people. 

 

For further information on Benchmark please visit www.benchmarkplc.com

 

 

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAPAMRTMBTBBMR
Date   Source Headline
5th Feb 202410:20 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
1st Feb 202410:26 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
1st Feb 202410:16 amRNSForm 8.3 - Benchmark Holdings plc
31st Jan 20242:03 pmRNSForm 8.3 - Benchmark Holdings
31st Jan 20247:00 amRNSTotal Voting Rights
30th Jan 202411:38 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
29th Jan 202412:18 pmRNSForm 8.3 - Benchmark Holdings plc
26th Jan 20243:19 pmRNSForm 8.3 - Benchmark Holdings Plc - Replacement
26th Jan 202410:48 amRNSForm 8.3 - Benchmark Holdings
26th Jan 20247:00 amRNSForm 8 (OPD) (Benchmark Holdings PLC)
24th Jan 20243:37 pmRNSForm 8.3 - Benchmark Holdings plc - Amendment
24th Jan 20248:46 amRNSForm 8.3 - Benchmark Holdings plc
23rd Jan 20242:40 pmRNSForm 8.3 - Benchmark Holdings Plc
23rd Jan 20242:25 pmRNSForm 8.3 - Benchmark Holdings Plc-Replacement
23rd Jan 20241:57 pmGNWForm 8.3 - [BENCHMARK HOLDINGS PLC - Opening Disclosure - 22 01 2024] - (CGAML)
23rd Jan 202411:20 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
23rd Jan 20247:00 amRNSNotice of Q1 Results
22nd Jan 20246:02 pmRNSRule 2.9 Announcement
22nd Jan 20245:14 pmRNSForm 8.3 - Benchmark Holdings Plc-Replacement
22nd Jan 20244:27 pmRNSForm 8.3 - Benchmark Holdings Plc
22nd Jan 20241:48 pmRNSForm 8.3 -Benchmark Holdings Plc
22nd Jan 20247:00 amRNSStrategic Review and Formal Sale Process
16th Jan 20245:30 pmRNSNotice of AGM - correction
9th Jan 20245:15 pmRNSPosting of Notice of AGM
12th Dec 20235:50 pmRNSNew Long Term Incentive Plan and PDMR Dealing
12th Dec 20231:54 pmRNSDirectorate Change
7th Dec 202312:00 pmRNSPublication of Annual Report and Notice of AGM
29th Nov 20237:01 amRNSDirectorate Change
29th Nov 20237:01 amRNSQ4 Results
29th Nov 20237:00 amRNSFull Year Results
6th Nov 202310:24 amRNSNotice of Q4 and Full Year Results
31st Oct 20237:00 amRNSTotal Voting Rights
10th Oct 202311:26 amRNSNew salmon broodstock licenses - correction
10th Oct 202310:06 amRNSGrant of two new salmon broodstock licenses
29th Sep 20237:00 amRNSTotal Voting Rights
21st Sep 20237:00 amRNSBlock Listing Six Monthly Return
31st Aug 20237:00 amRNSTotal Voting Rights
24th Aug 20237:00 amRNSQ3 Results
11th Aug 20237:00 amRNSNotice of Q3 Results
31st Jul 20237:00 amRNSTotal Voting Rights
30th Jun 20237:00 amRNSAppointment of Non-Executive Director
30th Jun 20237:00 amRNSTotal Voting Rights
31st May 20237:00 amRNSTotal Voting Rights
30th May 20233:30 pmRNSPCA Shareholding
30th May 202311:55 amRNSHolding(s) in Company
23rd May 20237:00 amRNSSecond Quarter and Interim results
5th May 20237:00 amRNSNotice of Q2 and Interim Results
28th Apr 20237:00 amRNSTotal Voting Rights
21st Apr 20231:00 pmRNSDirector Share Options
17th Apr 20237:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.